<DOC>
	<DOCNO>NCT00398515</DOCNO>
	<brief_summary>This phase I trial study side effect best dose temsirolimus give together lenalidomide treat patient previously treat multiple myeloma . Lenalidomide may stop growth multiple myeloma block blood flow cancer . Drugs use chemotherapy , temsirolimus , work different way stop growth cancer cell , either kill cell stop dividing . Temsirolimus may also stop growth cancer cell block enzyme need growth . Giving lenalidomide together temsirolimus may kill cancer cell .</brief_summary>
	<brief_title>Lenalidomide Temsirolimus Treating Patients With Previously Treated Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose CCI-779 ( temsirolimus ) give together lenalidomide patient previously treat multiple myeloma . SECONDARY OBJECTIVES : I . Determine toxicity regimen patient . II . Determine clinical response patient treat regimen . III . Determine pharmacokinetics regimen . IV . Determine pharmacodynamic effect regimen patient . V. Determine effect regimen immunological cellular serological parameter hematopoietic precursor cell . OUTLINE : This dose-escalation study CCI-779 . Patients receive temsirolimus intravenously ( IV ) 30 minute day 1 , 8 , 15 , 22 oral lenalidomide daily day 1-21 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Patients achieve least partial response 12 course may continue receive CCI-779 lenalidomide absence disease progression . Cohorts 3 patient receive escalate dos CCI-779 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Ten patient treated MTD . Patients undergo blood sample bone marrow collection periodically study treatment pharmacokinetic pharmacodynamic study , determine immunomodulatory effect CCI-779 lenalidomide .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Diagnosis multiple myeloma ( MM ) SalmonDurie stage IIA IIIA No stage B disease Meets ≥ 1 major AND 1 minor criterion OR ≥ 3 minor criterion The following consider major criterion : Plasmacytoma tissue biopsy Bone marrow plasmacytosis ≥ 30 % plasma cell Monoclonal paraprotein ≥ 3,500 mg/dL ( IgG ) ≥ 2,000 mg/dL ( IgA ) OR monoclonal protein ( BenceJones protein ) ≥ 1,000 mg 24hour urine collection The following consider minor criterion : Bone marrow plasmacytosis 1029 % marrow cellularity Monoclonal globulin spike &lt; 3,500 mg/dL ( IgG ) &lt; 2,000 mg/dL ( IgA ) Lytic bone lesion Decrease normal IgM ( &lt; 50 mg/dL ) , IgA ( &lt; 100 mg/dL ) , IgG ( &lt; 600 mg/dL ) Disease progression ≥ 1 prior systemic treatment regimen* MM ( e.g. , chemotherapy , highdose corticosteroid , thalidomide , bortezomib ) , define &gt; 25 % increase serum urine Mprotein No solitary plasmacytoma No nonsecretory MM ( absent serum urinary Mprotein ) ECOG performance status 02 Life expectancy &gt; 6 month Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Creatinine ≤ 2.0 mg/dL Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Fasting cholesterol ≤ 350 mg/dL Fasting triglycerides ≤ 400 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception Must agree donate blood , sperm , ova 4 week completion study treatment No prior concurrent malignancy myelodysplasia except follow : Basal cell squamous cell skin cancer Carcinoma situ cervix Localized cancer treat surgery evidence disease &gt; 5 year No history recurrent deep vein thrombosis ( DVT ) /pulmonary embolism ( PE ) DVT/PE occur therapeutic level anticoagulation Patients DVT/PE within past 6 month eligible provide receive full anticoagulation study treatment No active infection require oral intravenous antibiotic No uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude study compliance No known hepatitis B C No history allergic reaction attribute compound similar chemical biologic composition lenalidomide CCI779 See Disease Characteristics Prior lenalidomide allow Prior highdose chemotherapy stem cell transplantation allow More 4 week since prior chemotherapy antimyeloma systemic therapy ( e.g. , thalidomide , bortezomib , highdose corticosteroid ) recover No prior exposure lenalidomide mTOR inhibitor ( give together ) Treatment singleagent lenalidomide singleagent mTOR inhibitor allow No concurrent investigational agent No concurrent corticosteroids unless physiologic maintenance No concurrent antiretroviral therapy HIVpositive patient No concurrent myeloid growth factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) No concurrent grapefruit grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>